HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Rheumatic disease of pulmonary valve — Clinical Guidelines

Overview

Rheumatic disease leading to pulmonary valve dysfunction results in pulmonary regurgitation, often necessitating surgical intervention such as valve replacement to prevent right ventricular dysfunction and improve patient outcomes. 1 10

Diagnosis

Clinical Presentation: Symptoms may include dyspnea, fatigue, and signs of right heart failure.

Echocardiography: Essential for assessing severity of regurgitation and right ventricular function.

Cardiac MRI: Provides detailed assessment of right ventricular dimensions and function 1.

Electromagnetic Flow Velocity Catheters: Useful in quantifying regurgitant flow; ratio of backward to forward flow velocity signals helps in grading severity 11 12.

Management

Pulmonary Valve Replacement (PVR): Recommended for symptomatic patients or those with significant hemodynamic compromise. Techniques include homograft, PTFE bicuspid valve, and stentless bioprosthesis 2 4 7.

Surgical Timing: Optimal timing guided by right ventricular dimensions and function, with CMR thresholds aiding in decision-making 1.

Minimally Invasive Approaches: Off-pump techniques can reduce operation time and blood product use 3.

Device Selection: PTFE bicuspid valves show promising long-term outcomes but require monitoring for reintervention 2.

Special Populations

Pediatrics: PTFE bicuspid valves have been used successfully in younger patients 2.

Elderly: Case reports indicate successful surgical correction with stentless bioprosthesis in elderly patients 7.

Comorbidities: Specific considerations for comorbidities like endocarditis should guide surgical intervention timing and choice of valve 7 10.

Key Recommendations

Consider Pulmonary Valve Replacement for Symptomatic Patients with Severe Pulmonary Regurgitation to prevent right ventricular dysfunction (Evidence: Moderate 1 2).

Utilize Cardiac MRI to Assess Right Ventricular Dimensions and Function for optimal timing of PVR (Evidence: Moderate 1).

Evaluate and Select Valve Type Based on Patient Age and Long-term Durability, favoring PTFE bicuspid valves in pediatric and select adult populations (Evidence: Moderate 2 7).

References

1 Ghandour HZ, Hammoud MS, Zia A, Rajeswaran J, Najm HK, Pettersson G et al.. Characterization of Favorable Right Ventricular Dimensions for Optimal Reverse Remodeling Following Pulmonary Valve Replacement. Seminars in thoracic and cardiovascular surgery 2024. link 2 Kim ER, Lee C, Lee CH, Cho SH. Long-term Outcomes of Polytetrafluoroethylene Bicuspid Pulmonary Valve Replacement. The Annals of thoracic surgery 2024. link 3 Chen Q, Turner M, Caputo M, Stoica S, Marianeschi S, Parry A. Pulmonary valve implantation using self-expanding tissue valve without cardiopulmonary bypass reduces operation time and blood product use. The Journal of thoracic and cardiovascular surgery 2013. link 4 Talwar S, Sharma P, Mishra S, Choudhary SK, Gulati GS, Airan B. A modified technique for pulmonary valve replacement with a homograft. Journal of cardiac surgery 2011. link 5 George I, Shah JN, Bacchetta M, Stewart A. Stentless bioprosthesis in a valved conduit: implications for pulmonary reconstruction. The Annals of thoracic surgery 2009. link 6 Schievano S, Petrini L, Migliavacca F, Coats L, Nordmeyer J, Lurz P et al.. Finite element analysis of stent deployment: understanding stent fracture in percutaneous pulmonary valve implantation. Journal of interventional cardiology 2007. link 7 Ali AA, Halstead JC, Hosseinpour AR, Ali ZA, Kumar S, Wallwork J. Replacement of a regurgitant pulmonary valve with a stentless bioprosthesis. The Annals of thoracic surgery 2004. link01440-1) 8 Cooper LC. Symptomatic papillary tumour of the pulmonary valve. Postgraduate medical journal 1982. link 9 Lutz JF, Hagan AD, Vieweg WV, Thompson SI, Aaron BL. "Pseudo-tumor" of the right ventricular outflow tract and congenital pulmonary valve regurgitation: a case report. American heart journal 1980. link90150-7) 10 Faruqui AM, Silverman ME. Isolated acquired pulmonary valve regurgitation. Report of long-term follow-up. British heart journal 1978. link 11 Rohmer J, Van Der Mark F, Zijlstra WG. Pulmonary valve incompetence. II. Application of electromagnetic flow velocity catheters in children. Cardiovascular research 1976. link 12 Van Der Mark F, Rohmer J, Zijlstra WG. Pulmonary valve incompetence. I. Evaluation using electromagnetic flow velocity catheters and a new valve insufficiency analyser. Cardiovascular research 1976. link

Rheumatic disease of pulmonary valve